A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral MM120 Compared to Placebo in the Treatment of Adults With Generalized Anxiety Disorder - Voyage
Status: Recruiting
Location: See all (32) locations...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 74
Healthy Volunteers: f
View:
• Diagnosis of GAD per DSM-5
• Male or female aged 18 to 74
• HAM-A Total Score ≥20
Locations
United States
Arizona
Lighthouse Psychiatry
RECRUITING
Gilbert
California
Kadima Neuropsychiatry Institute
RECRUITING
La Jolla
UCSF Department of Neurology
RECRUITING
San Francisco
Psychedelic Science Institute
NOT_YET_RECRUITING
Santa Monica
Colorado
Mountain View
RECRUITING
Denver
Florida
Clinical Neuroscience Solutions Inc.
RECRUITING
Jacksonville
Accel Research Sites - Lakeland CRU
ACTIVE_NOT_RECRUITING
Lakeland
Segal Trials
ACTIVE_NOT_RECRUITING
Lauderhill
Georgia
Atlanta Center for Medical Research
RECRUITING
Atlanta
iResearch Atlanta
RECRUITING
Decatur
CenExel iResearch, LLC
RECRUITING
Savannah
Illinois
Uptown Research Institute
RECRUITING
Chicago
Massachusetts
Adams Clinical Boston
RECRUITING
Boston
Adams Clinical Watertown
ACTIVE_NOT_RECRUITING
Watertown
Missouri
University of Missouri Health Care
RECRUITING
Columbia
New Jersey
Hassman Research Institute
RECRUITING
Marlton
New York
Adams Clinical Harlem
NOT_YET_RECRUITING
New York
New York State Psychiatric Institute (NYSPI)
NOT_YET_RECRUITING
New York
Spectrum Neuroscience and Treatment Institute
RECRUITING
New York
Adams Clinical Bronx
NOT_YET_RECRUITING
The Bronx
Ohio
Cleveland Clinic Lutheran Hospital
RECRUITING
Cleveland
Oregon
Summit Headlands LLC
RECRUITING
Portland
Pennsylvania
Scranton Medical Institute
RECRUITING
Moosic
Adams Clinical Philadelphia
RECRUITING
Philadelphia
South Carolina
Coastal Carolina Research Center
RECRUITING
North Charleston
Tennessee
Clinical Neuroscience Solutions, Inc.
RECRUITING
Memphis
Texas
Austin Clinical Trial Partners
NOT_YET_RECRUITING
Austin
BioBehavioral Research of Austin
ACTIVE_NOT_RECRUITING
Austin
Dell Medical School, University of Texas at Austin
RECRUITING
Austin
Utah
Cedar Clinical Research
RECRUITING
Draper
Vermont
Memory Clinic Inc.
RECRUITING
Bennington
Washington
Seattle Neuropsychiatric Treatment Center
RECRUITING
Seattle
Contact Information
Primary
Mind Medicine Clinical Trials Info Requests
clinicaltrials@mindmed.co
332-282-0479
Time Frame
Start Date: 2024-12-11
Estimated Completion Date: 2026-11
Participants
Target number of participants: 200
Treatments
Placebo_comparator: Arm 1 - Placebo
A substance that is designed to have no therapeutic value
Experimental: Arm 2 - 100µg MM120 (LSD D-Tartrate)
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Related Therapeutic Areas
Sponsors
Leads: Mind Medicine, Inc.